ArticleDiagnostics (Basel, Switzerland)2015
Diagnostics for Developing Countries.
Article in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.PloS one · 2019Pooled it
- Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2018Pooled it
- Finger-actuated microfluidic device for point-of-care circulating cell-free nucleic acid extraction.Lab on a chip · 2026Article
- Assessments of the in vitro diagnostic kits landscape and availability from selected hospitals and health-related facilities in Addis Ababa, Ethiopia.BMC health services research · 2026Article
- Article
- Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors.Diagnostics (Basel, Switzerland) · 2026Review
- Lifetime Probability of Developing Migraine: A Novel Epidemiological Perspective Based on Global Burden of Disease Data.Pain research & management · 2026Article
- Advancing Point-of-Care Healthcare Diagnostics to Tackle Future Outbreaks and Pandemics: Nanotechnology-Driven Developments and Impact on Rapid Pathogen Detection.Environment & health (Washington, D.C.) · 2025Article
- Identifying pathways to achieve diverse objectives of the National Essential Diagnostics List: developing an assessment framework based on field studies in Cambodia, Indonesia, Lao PDR, and the Philippines.Tropical medicine and health · 2025Article
- Emerging Trends in Point-of-Care Technology Development for Oncology in Low- and Middle-Income Countries.JCO global oncology · 2025Review
- Surviving Bad News: Health Information Without Treatment Options.American economic review. Insights · 2025Article
- Derivation and validation of a clinical predictive model for longer duration diarrhea among pediatric patients in Kenya using machine learning algorithms.BMC medical informatics and decision making · 2025Article
- Advancing the safe motherhood initiative: A qualitative and sentiment analysis of local physician's perspectives on antibiotic self-medication during pregnancy in a low- and middle-income country.PLOS global public health · 2025Article
- Quality and resilience of clinical laboratories in Rwanda: a need for sustainable strategies.Global health action · 2024Article
- Next-generation rapid phenotypic antimicrobial susceptibility testing.Nature communications · 2024Review
- From prediction to practice: mitigating bias and data shift in machine-learning models for chemotherapy-induced organ dysfunction across unseen cancers.BMJ oncology · 2024Article
- Urine dipstick for screening plasma glucose and bilirubin in low resource settings: a proof-of-concept study.Advances in laboratory medicine · 2023Article
- Article
- Healthcare provider-targeted mobile applications to diagnose, screen, or monitor communicable diseases of public health importance in low- and middle-income countries: A systematic review.PLOS digital health · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improving the availability of high quality diagnostic tests for infectious diseases is a global priority. Lack of access by people living in low income countries may deprive them of life saving treatment and reduces opportunities to prevent onward transmission and spread of the disease. Diagnostic laboratories are often poorly resourced in developing countries, and sparsely distributed. Improved access may be achieved by using tests that do not require laboratory support, including rapid tests for use at the point-of-care. Despite increased interest, few new in vitro diagnostic (IVD) products reach the majority populations in low income countries. Barriers to uptake include cost and lack of robustness, with reduced test performances due to environmental pressures such as high ambient temperatures or dust. In addition to environmental factors test developers must consider the local epidemiology. Confounding conditions such as immunosuppression or variations in antigen presentation or genotype can affect test performance. Barriers to product development include access to finance to establish manufacturing capacity and cover the costs of market entry for new devices. Costs and delays may be inflated by current regulatory preregistration processes to ensure product safety and quality, and more harmonized approaches are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.